Roche’s Tecentriq With Lurbinectedin Increases Survival From Small-Cell Lung Cancer, Study Says Late-stage trials showed the combination led to a 27% reduction in the risk of death, the company said ...

Tecentriq may be used with the medicines cobimetinib and vemurafenib in patients with melanoma when their skin cancer: has spread to other parts of the body or cannot be removed by surgery, and; ...

Tecentriq can cause serious side effects, including: Lung problems (pneumonitis)–signs and symptoms of pneumonitis may include new or worsening cough, shortness of breath, and chest pain ...

Tecentriq can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life ...

Tecentriq is available as a liquid solution that’s given as an IV infusion (an injection into your vein over a period of time). You’ll receive infusions at your doctor’s office or a clinic.

The Tecentriq combination showed a statistically significant improvement in RFS in t. Genentech, a unit of Roche Holdings AG (OTC: RHHBY), ...

Merck’s MRK primary strength lies in oncology, propelled by its blockbuster PD-L1 inhibitor, Keytruda, which fuels robust ...

Zepzelca plus Tecentriq improved PFS and OS in ES-SCLC patients compared to Tecentriq alone, with a median PFS of 5.4 months versus 2.1 months. The combination therapy showed a median OS of 13.2 ...

Tecentriq with chemotherapy did not significantly improve EFS in TNBC patients, with a four-year EFS rate of 85.2% versus 81.9% for placebo. No overall survival benefit was observed with Tecentriq, ...

“Tecentriq is now the first and only cancer immunotherapy available for adjuvant treatment of NSCLC, introducing a new era where people diagnosed with early lung cancer may have the opportunity ...

Roche has voluntarily withdrawn the U.S. indication of Tecentriq for treating a form of bladder cancer following consultation with the Food and Drug Administration (FDA), the Swiss drugmaker said ...

Roche said Tecentriq combined with lurbinectedin shows significant survival benefits for patients with extensive-stage small cell lung cancer. The Swiss pharmaceutical company said Tuesday that ...